Skip to main content
. 2019 Aug 21;154(10):e193019. doi: 10.1001/jamasurg.2019.3019

Table 1. Demographic, Clinicopathologic, and Treatment Characteristics of Patients With Pancreatic Cancer Who Underwent Pancreatic Resection.

Characteristic Data (n = 2786)a
Age, mean (SD), y 67.0 (10.7)
Sex
Male 1394 (50.0)
Female 1392 (50.0)
Race
White 2308 (82.8)
Black 152 (5.5)
Asian/Pacific Islander 313 (11.2)
Other/unknown 13 (0.5)
Elixhauser comorbidity index score, mean (SD)b 13.9 (8.9)
Tumor grade
Well differentiated 295 (10.6)
Moderately differentiated 1373 (49.3)
Poorly differentiated or undifferentiated 949 (34.1)
Unknown 169 (6.1)
T category
T1 204 (7.3)
T2 435 (15.6)
T3 2147 (77.1)
N category
N0 1054 (37.8)
N1 1725 (61.9)
NX 7 (0.3)
Stage
I 399 (14.3)
II 2387 (85.7)
Chemotherapy
None 1070 (38.4)
Preoperative 89 (3.2)
Postoperative 1238 (44.4)
Preoperative and postoperative 50 (1.8)
Unknown 339 (12.2)
Radiotherapy 874 (31.4)
Pancreatic resection
Pancreaticoduodenectomy 2207 (79.2)
Distal pancreatectomy 387 (13.9)
Total pancreatectomy 98 (3.5)
Other 94 (3.4)
Complication within 30 d 1037 (37.2)
Readmission within 30 d 565 (20.3)
Length of stay, median (IQR), d 12 (9-18)
Surgery hospitalization costs, mean (SD), $c 60 939 (56 779)
Follow-up, median (IQR), mo 20 (10-35)
Vital status
Death due to pancreatic cancer 2020 (72.5)
Death due to other cause 247 (8.9)
Death due to unknown cause 55 (2.0)
Alive 464 (16.7)
High-volume hospital 1297 (46.6)
NCI-designated cancer center 1127 (40.5)
Teaching hospital 1428 (51.3)

Abbreviations: IQR, interquartile range; NCI, National Cancer Institute.

a

Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages have been rounded and may not total 100.

b

Scores range from −11 to 62, with higher scores indicating a greater number of comorbidities.

c

Includes the index surgical hospitalization and readmissions within 30 days.